Abbisko Therapeutics Co. Ltd.

Plus: Seismic adds $121M in series B round and updates from Merck KGaA, Abbisko, Perpetual Medicines, CRISPR Therapeutics and YolTech

Deep antibody expertise is a platform for leaps in new assets and technologies as Asia biotechs become increasingly competitive

Investors rewarded Revolution for preclinical KRAS (ON) data at AACR23, as a wave of dual KRAS (ON/OFF) inhibitors at the meeting gear up for the clinic

Plus new COO, CMO at I-Mab, updates from TwinStrand, Chimera, CyTek and more

Plus nutrition co Faeth raises $20M; ADC/Tanabe deal, and updates from Dyne, Lilly, Abbisko and more

Plus first day of trading for MiNK, Abbisko and updates Rectify, Roche, Avadel

It’s no longer only MNCs. CEOs from domestic biotechs, academia and investment communities a growing source of China CEOs

Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of R&D, succeeding Junichi Koga, who is retiring after more than a dozen years at the

President Biden nominated Chiquita Brooks-LaSure as CMS administrator. Brooks-LaSure previously served under the Obama administration as deputy director for policy at CMS’ Center for

Carlyle leads Abbisko’s $123M series DShanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company